Stock quote - Summary

Amryt Pharma
AMYT: 127.50 +2.50 ( +2.00 %) delayed: 17:09PM
Bid price 125.00 High price 125.00
Ask price 130.00 Low price 124.00
Open price 125.00 Spread 3.85%
Prev close 127.50 Volume 177,922

Amryt Pharma - Share price charts

Historic - 6 months

Advanced Amryt Pharma charts >

Amryt Pharma - Share price information
Name Amryt Pharma Epic AMYT
Activities Amryt Pharma plc's (formerly Fastnet Equity, formerly Fastnet Oil & Gas plc, formerly Sterling Green Group plc, formerly Hamilton Partners plc) is a specialty biopharmaceutical company focused on developing and delivering innovative new treatments to help improve the lives of patients with rare or orphan diseases. The Company is building a diversified portfolio of commercially attractive, best-in-class, proprietary new drugs to help address some of these rare and debilitating illnesses for which there are currently no available treatments. The Company holds an exclusive licence to sell Lojuxta (lomitapide) for adults, across the European Economic Area, Middle East and North Africa, Turkey and Israel. Lojuxta is used to treat a rare life-threatening disease called Homozygous Familial Hypercholesterolemia, which impairs the body's ability to remove LDL cholesterol ('bad' cholesterol) from the blood. This typically results in extremely high blood LDL cholesterol levels, leading to aggressive and premature narrowing and blocking of arterial blood vessels. If left untreated, heart attack or sudden death may occur in childhood or early adulthood. Amryt's lead drug candidate, AP101 (Episalvan), is a potential treatment for Epidermolysis bullosa (EB), a rare and distressing genetic skin disorder affecting young children for which there is currently no treatment. It is currently in Phase 3 clinical trials. The global market opportunity for EB is estimated to be in excess of EUR 1.3 billion. Amryt's earlier stage product AP102 is focused on developing novel, next generation somatostatin analogue (SSA) peptide medicines for patients with rare neuroendocrine diseases, where there is a high unmet medical need, including acromegaly and Cushing's disease. ISIN GB00BKLTQ412
Latest Share Price (p) 127.50 Net Gearing (%) 90.69
Market Capitalisation (pm) 193.12 Gross Gearing (%) 104.57
Shares in issue (m) 154.50 Debt Ratio 105.37
P/E Ratio -13.33 Debt-to-Equity Ratio 0.86
Total dividends per share (p) 0.00 Assets / Equity Ratio -21.86
Dividend Yield (%) 0.00 Price to book value -59.79
Dividend Cover 0.00 ROCE (%) -42.82
Earning per share (p) -9.38 EPS Growth (%) 19.97
52-week high / low (p) 141.00 / 12.13 DPS Growth (%) n/a
Amryt Pharma - Broker views
Date Broker Recommendation Price Old target price New target price Notes
24 Apr Stifel Buy 60.00 60.00 Reiterates
06 Apr Stifel Buy 60.00 60.00 Reiterates
04 Apr Stifel Buy 60.00 60.00 Reiterates
06 Feb Stifel Buy 49.00 49.00 Reiterates

More Amryt Pharma broker views >

Amryt Pharma - Director deals
Date Director Type Volume / Price Trade value
07 Jan 2020 Joe Wiley Buy 7,999 @ 121.90p £9,750.78
30 Aug 2019 Ray Stafford Placing 918,273 @ 90.00p £826,445.70
11 Oct 2017 Markus Ziener Placing 132,955 @ 20.00p £26,591.00
11 Oct 2017 James Culverwell Placing 221,592 @ 20.00p £44,318.40
11 Oct 2017 Rory Nealon Placing 221,592 @ 20.00p £44,318.40

More Amryt Pharma director deals >

Risk warning: Remember the price of shares can go down as well as up, and you are not guaranteed to get back the amount that you originally invested.
Click here to read the full warning.